World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 

Going To Court: The EU Sues AstraZeneca

It has been a relationship of characterised by bitterness and misunderstanding. It began with a poorly negotiated agreement – poor, that is, from the European Union perspective – between Brussels and AstraZeneca for the supply of COVID-19 vaccine doses. Less rigorous in terms of penalties and consequences than the UK-AstraZeneca deal, the EU version was very much the poor cousin, giving the company much latitude in terms of production schedules and delays. While the UK government managed to insert the relevant clause allowing it to terminate the deal and invoke punitive clauses against AstraZeneca, the EU contract makes no mention of it. But in August 2020, little heed to this was paid by EU negotiators, starry-eyed to the company’s promise to supply 300 million doses of their COVID-19 vaccine, with the option of securing a further 100 million. The result was a defanged deal based on gentlemanly promises.

Delays and supply problems duly manifested. In January, the drugs company informed the European Commission that it would ship fewer doses to the bloc than was originally promised. “While there is no scheduled delay to the start of shipments of our vaccine should we receive approval in Europe,” stated an AstraZeneca spokesperson, “initial volumes will be lower than originally anticipated due to reduced yields at a manufacturing site within our European supply chain.” Within the first three months, 30 million jabs of the initial 90 million made its way to the EU. Little by way of improvement was shown in the next quarter: 70 million doses from 180 million promised.

The delays and supply disruptions have resulted in a sluggish immunisation effort in the EU and also done its bit to fray relations between the bloc and the UK. EU officials have looked on, envious and irritated at the UK’s own, comparatively more successful and rapid immunisation campaign.

It is precisely that latitude of behaviour on the part of the company that is now being challenged in the courts. The European Commission is suing AstraZeneca, arguing that the company has not discharged its obligations under the vaccine supply contract nor possess an appropriate plan for the timely delivery of doses. “Our priority,” wrote Stella Kyriakides, the EU Commissioner for Health and Food Safety, “is to ensure COVID-19 vaccine deliveries take place to protect the health of [EU citizens].”

In court, the EU’s Rafaël Jafferali submitted that, “We demand deliveries by the end of June and we also demand with immediate effect the use of all plants listed in the contract.” A central contention is that AstraZeneca had preferred not utilising all those mentioned (four are noted, two of which are located in the UK); the EU argument is that the company was under an obligation to use all the plants. Not doing so put it in breach of the contract.

AstraZeneca’s Hakim Boularbah’s submission showed how far apart the parties are in terms of understanding the contract. “There is no obligation to use the factories,” came the argument. The point is crucial, given that the company has only utilised sites in Belgium and the Netherlands, sparing the UK outfits run by Oxford Biomedica and Cobra Biologics. There has also been no resort to the Catalent factory in the United States, mentioned in the contract as a possible “back-up supply site”.

Whatever the merits of the EU’s legal arguments, certain countries within the bloc have been circumspect about dragging the company through the courts. Germany and France have expressed misgivings. As one diplomat explained to Politico, “What can we do in practical terms if AstraZeneca says, ‘Take a closer look at our production sites: We just have no vaccines’?” There were also questions about the enforceability of any ruling. The entire process risks becoming a vacuous display of anger without effect.

Then comes the issue of bad publicity. Reluctance to take COVID-19 vaccines is a prevalent sentiment within the bloc. Reliability and trust is already being tested. A number of EU diplomats worry that the lawsuit may have the effect of further tarnishing a company that is already struggling in terms of its brand.

Much of this can be put down to the sabotaging efforts of various leaders within the Union itself, not least of all French President Emmanuel Macron, who has found it hard to resist sniping at the AstraZeneca vaccine. At the end of January, he opined that the vaccine was “quasi-effective” for those over 65 years old. The following month, he changed his mind. The result: French confidence in the vaccine, along with a good deal of Europe’s, has been shattered.

This distinctly sour note continues the profoundly disunited state of affairs in efforts to battle the global pandemic. Vaccine patriotism and parochialism continue to limit access. Pharmaceutical giants continue to maintain IP protections even as they struggle to maintain supply. And the EU’s own measure of competence in negotiations and planning has been found wanting.

Dr. Binoy Kampmark was a Commonwealth Scholar at Selwyn College, Cambridge. He lectures at RMIT University, Melbourne. Email: bkampmark@gmail.com

© Scoop Media

 
 
 
World Headlines

 


Covid-19: Vaccines Donated Next Year, ‘Too Late For Those Who Are Dying Today’

Millions more COVID vaccines need to be donated now to save lives and help the UN health agency reach the key global target of having 70 per cent of all national populations vaccinated, by the middle of 2022... More>>


UN News: Landmark G7 Agreement Pledges 870 Million COVID-19 Vaccine Doses, Half By End-2021

A senior UN official welcomed on Sunday, the Group of Seven (G7) leading industrialized nations’ commitment to immediately share at least 870 million doses of COVID-19 vaccines, supporting global access and helping to end the acute phase of the pandemic... More>>



OECD: G20 GDP Returns To Pre-pandemic Level In The First Quarter Of 2021, But With Large Differences Across Countries

Gross domestic product (GDP) of the G20 area returned to pre-pandemic level in the first quarter of 2021, growing by 0.8% compared with the fourth quarter of 2020. However, this figure conceals large differences across countries... More>>

Focus On: UN SDGs


COP26: Progress Made As May-June UN Climate Change Session Closes

The May-June Climate Change Session, the first to have been held virtually to prepare for the UN Climate Change Conference (COP26) to be held at the end of the year in Glasgow, Scotland, closed today... More>>

UNFCCC: Halving Emissions By 2030 Is New Normal - Race To Zero Anniversary
Over 4,500 non-state actors from across the global economy have committed to halving emissions by 2030, joining the UN-backed Race to Zero campaign... More>>


UN: Tackling Biodiversity & Climate Crises Together And Their Combined Social Impacts

Unprecedented changes in climate and biodiversity, driven by human activities, have combined and increasingly threaten nature, human lives, livelihoods and well-being around the world... More>>